Retinal Vein Occlusion Treatment Market 2023 to 2033: Advanced R&D Process Strategies

The global Retinal Vein Occlusion Treatment market size is predicted to be worth US$ 2.3 billion in 2023, with a compound yearly growth rate (CAGR) of 5.9% to reach US$ 4.7 billion from 2023 to 2033. Retinal vein occlusion is one of the most common retinal vascular disorders in the elderly, affecting adults over the age of 65. Age is a key risk factor for retinal vein occlusion. The incidence of retinal vein blockage is projected to rise as the geriatric population grows.

North America held a significant percentage of the global retinal vein occlusion market in 2022 due to numerous upgraded medical facilities, an increase in the occurrence of eye ailments, technological improvements, and an increase in the ageing population. The Asia Pacific retinal vein occlusion market is anticipated to grow at a 6.5% CAGR between 2023 and 2033. Rising ocular illness prevalence in Asia Pacific, particularly in China, Singapore, Indonesia, and other Southeast Asian countries, as well as rising health expenditures, are expected to drive market expansion in East and South Asia from 2023 to 2033. During the forecast years, Europe is expected to hold the second-largest market share. The growing older population, combined with increased healthcare spending, is propelling the retinal vein occlusion market in this region forward.

In 2022, the branch retinal vein occlusion sector grew the most in terms of worldwide retinal vein occlusion medicines revenue. As the prevalence of high blood pressure, cardiovascular disease, and glaucoma rises, this sector is likely to dominate the market.

Market Competition

Key players in the Retinal Vein Occlusion Treatment market are AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Kodiak Sciences Inc., Chugai Pharmaceuticals, and Novartis AG among others.

Get More Details@ https://www.futuremarketinsights.com/reports/retinal-vein-occlusion-treatment-market

Key Segments Profiled in the Retinal Vein Occlusion Treatment Industry Survey

By Drug Class:

  • Ranibizumab
  • Dexamethasone
  • Aflibercept
  • Bevacizumab

By Type:

  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion

By Diagnosis:

  • Optical Coherence Tomography
  • Fundoscopic Examination
  • Fluorescein Angiography

By End User:

  • Hospitals
  • Research and Academics
  • Specialty Clinics

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more